Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

NCT06109181 is registered in ClinicalTrials.gov with Lexeo Therapeutics as lead sponsor.

NCT NCT06109181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06109181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Lead sponsor
Lexeo Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 29, 2024
Completion date
March 31, 2027
Enrollment
10 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmogenic cardiomyopathy, pkp2-acm, pkp2-arvc